



IN C3G, FABHALTA CAN HELP YOU GO FORWARD

Patient portrayal.



The first and only FDA-approved oral treatment for adults with C3G, to reduce proteinuria.

C3G, complement 3 glomerulopathy.

Approved Use

What is FABHALTA?

FABHALTA is a prescription medicine used to treat adults with a kidney disease called complement 3 glomerulopathy (C3G), to reduce protein in the urine (proteinuria).

It is not known if FABHALTA is safe and effective in children with C3G.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

Important Safety Information

What is the most important information I should know about FABHALTA?

FABHALTA is a medicine that affects part of your immune system and may lower your ability to fight infections.

- **FABHALTA increases your chance of getting serious infections caused by encapsulated bacteria**, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.

AN ULTRA-RARE DISEASE LIKE C3G CAN LEAD TO A DIFFICULT JOURNEY

FABHALTA: THE FIRST AND ONLY FDA-APPROVED ORAL TREATMENT FOR ADULTS WITH C3G, TO REDUCE PROTEINURIA (PROTEIN IN THE URINE)

It may have been frustrating to not have an approved treatment option for C3G



You've followed your doctor's recommendation so far, but you may want a therapy that's specific for your disease



Fortunately, there's a way for you to fight back against C3G



FABHALTA[®]
(iptacopan) 200 mg capsules

Act now and ask your doctor about FABHALTA today!

“Previously, there has not been something specific for C3G.”

— Real C3G patient

Patient portrayal.



Important Safety Information (continued)

What is the most important information I should know about FABHALTA? (continued)

- **FABHALTA increases your chance of getting serious infections caused by encapsulated bacteria**, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.
 - You must complete or update your vaccinations against *Streptococcus pneumoniae* and *Neisseria meningitidis* at least 2 weeks before your first dose of FABHALTA.
 - If you have not completed your vaccinations and FABHALTA must be started right away, you should receive the required vaccinations as soon as possible.
 - If you have not been vaccinated and FABHALTA must be started right away, you should also receive antibiotics to take for as long as your health care provider tells you.
 - If you have been vaccinated against these bacteria in the past, you might need additional vaccinations before starting FABHALTA. Your health care provider will decide if you need additional vaccinations.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.



FABHALTA[®]
(iptacopan) 200 mg capsules

TRANSFORM THE WAY YOU REDUCE PROTEINURIA IN C3G WITH FABHALTA



The first and only FDA-approved oral treatment for adults with C3G, to reduce proteinuria



An oral option that can fit into your daily routine

TAKE THE NEXT STEP IN YOUR JOURNEY WITH FABHALTA

Important Safety Information (continued)

What is the most important information I should know about FABHALTA? (continued)

- **FABHALTA increases your chance of getting serious infections caused by encapsulated bacteria**, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.
 - Vaccines do not prevent all infections caused by encapsulated bacteria. **Tell your health care provider or get emergency medical care right away if you get any of these signs and symptoms of a serious infection:**
 - Fever with or without shivers or chills
 - Fever with chest pain and cough
 - Fever with high heart rate
 - Headache and fever
 - Confusion
 - Clammy skin
 - Fever and rash
 - Fever with breathlessness or fast breathing
 - Headache with nausea or vomiting
 - Headache with stiff neck or stiff back
 - Body aches with flu-like symptoms
 - Eyes sensitive to light

Patient
portrayal.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.


 **FABHALTA**[®]
(iptacopan) 200 mg capsules

About
FABHALTA

FABHALTA: A FIRST-OF-ITS-KIND TARGETED C3G TREATMENT

FABHALTA is the first and only FDA-approved oral complement 3 glomerulopathy (C3G) treatment that targets the complement system. FABHALTA is a treatment for adults with C3G to reduce proteinuria.

In C3G, the complement system (a part of your immune system that helps fight infections) becomes overactive, resulting in a buildup of C3 in your kidneys as well as inflammation.



Important Safety Information (continued)

What is the most important information I should know about FABHALTA? (continued)

Your health care provider will give you a Patient Safety Card about the risk of serious infections. Carry it with you at all times during treatment and for 2 weeks after your last dose of FABHALTA. Your risk of serious infections may continue for a few weeks after your last dose of FABHALTA. It is important to show this card to any health care provider who treats you. This will help them diagnose and treat you quickly.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

 **FABHALTA**[®]
(iptacopan) 200 mg capsules

FABHALTA CLINICAL STUDY OVERVIEW

The APPEAR-C3G trial for adults with C3G who had never received a kidney transplant studied the percentage reduction in urine protein-to-creatinine ratio, or UPCR, a test used to measure protein in urine. In this study, urine samples were collected over 24 hours, with results from the start of the study compared against those after 6 months.

Safety and effectiveness of FABHALTA in patients with recurrent C3G following kidney transplant have not been established.

What was studied? (Primary Study Objective)

The **reduction in UPCR**, a test used to measure protein in urine (proteinuria), after 6 months of treatment with FABHALTA or placebo.

Who was studied?

74 adults with biopsy-confirmed C3G who had never received a kidney transplant

- All patients had elevated proteinuria (UPCR ≥ 1.0 g/g) and eGFR ≥ 30 mL/min/1.73 m² at the start of the study, never had a kidney transplant, and were receiving a stable dose of maximally tolerated blood pressure medications (ACEi/ARB) with or without other background therapies 90 days prior to starting the study and throughout the study

How was the study done?

- For the first 6 months, 38 people received FABHALTA 200 mg twice daily and 36 people received placebo (sugar pill) twice daily
- During the next 6 months (extension period), all participants took FABHALTA 200 mg twice daily

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate.

Important Safety Information (continued)

What is the most important information I should know about FABHALTA? (continued)

FABHALTA is only available through a program called the FABHALTA Risk Evaluation and Mitigation Strategy (REMS). Before you can take FABHALTA, your health care provider must:

- Enroll in the FABHALTA REMS program.
- Counsel you about the risk of serious infections caused by certain bacteria.


Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.




Patient portrayal.

 **FABHALTA**[®]
(iptacopan) 200 mg capsules

Primary Study Objective
Change in Proteinuria at 6 Months



FABHALTA SUBSTANTIALLY REDUCED PROTEINURIA COMPARED TO PLACEBO AT 6 MONTHS



DID YOU KNOW?

Increasing levels of proteinuria over time is an important indicator that your C3G may be getting worse.

Ask your doctor how FABHALTA can help reduce proteinuria.

Important Safety Information (continued)

What is the most important information I should know about FABHALTA? (continued)

FABHALTA is only available through a program called the FABHALTA Risk Evaluation and Mitigation Strategy (REMS). Before you can take FABHALTA, your health care provider must: (continued)

- Give you written information about the symptoms of serious infections.
- Make sure that you are vaccinated against serious infections caused by encapsulated bacteria.
- Make sure you receive antibiotics if you need to start FABHALTA right away and you are not up-to-date on your vaccinations.
- Give you a **Patient Safety Card** about your risk of serious infections.

Who should NOT take FABHALTA?

Do not take FABHALTA if you:


- Are allergic to FABHALTA or any of the ingredients in FABHALTA.
- Have a serious infection caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, or *Haemophilus influenzae* type b, when you start FABHALTA.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

 **FABHALTA**[®]
(iptacopan) 200 mg capsules

WITH FABHALTA, PROTEINURIA REDUCTION AT MONTH 6 WAS SUSTAINED THROUGH MONTH 12

Percentage Change in UPCR (g/g) From Baseline Over 12 Months



UPCR, urine protein-to-creatinine ratio.

In the study, another measurement called first morning void (FMV) was taken to measure protein in the urine. FMV refers to the first urination of the day after you wake up and is more concentrated at this time.

- Although there was a numerical improvement at Month 6 between FABHALTA and placebo (sugar pill) in the reduction of proteinuria measured by FMV, this may not be attributable to FABHALTA alone and could be due to chance.

Important Safety Information (continued)

Before you take FABHALTA, tell your health care provider about all your medical conditions, including if you:

- Have an infection or fever.
- Have liver problems.
- Are pregnant or plan to become pregnant. It is not known if FABHALTA will harm your unborn baby.
- Are breastfeeding or plan to breastfeed. It is not known if FABHALTA passes into your breast milk. You should not breastfeed during treatment and for 5 days after your final dose of FABHALTA.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

 **FABHALTA[®]**
(iptacopan) 200 mg capsules

SAFETY PROFILE OF FABHALTA

The most common side effects of FABHALTA in adults include:

- Headache
- Nasal congestion, runny nose, cough, sneezing, and sore throat (nasopharyngitis)
- Diarrhea
- Feeling dizzy
- Pain in the stomach (abdomen)
- Infections (bacterial and viral)
- Nausea
- Rash



Because of the risk of serious infections, FABHALTA is only available through a Risk Evaluation and Mitigation Strategy (REMS) program that requires vaccinations.

See pages **9-10** for more information on the risk of serious infections and the need for vaccinations.

See page **11** for more on the FABHALTA REMS program.

FABHALTA may cause serious side effects, including increased cholesterol and triglyceride (lipid) levels in your blood. Your health care provider will do blood tests to check your cholesterol and triglycerides during treatment with FABHALTA. Your health care provider may start you on a medicine to lower your cholesterol if needed.

Tell your health care provider about any side effect that bothers you or that does not go away. These are not all of the possible side effects of FABHALTA.

Important Safety Information (continued)

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking FABHALTA with certain other medicines may affect the way FABHALTA works and may cause side effects.

Know the medicines you take and the vaccines you receive. Keep a list of them to show your health care provider and pharmacist when you get a new medicine.

Please see additional Important Safety Information throughout and on pages **12-13**, and full Prescribing Information, including Boxed WARNING and Medication Guide.

 **FABHALTA**[®]
(iptacopan) 200 mg capsules

WHY YOU NEED CERTAIN VACCINATIONS BEFORE STARTING FABHALTA

What is the most important information I should know about FABHALTA?

FABHALTA is a medicine that affects part of your immune system and may lower your ability to fight infections.

The reason you need certain vaccinations before starting treatment is because **FABHALTA increases your chance of getting serious infections caused by encapsulated bacteria**, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.

You must complete or update the following vaccinations at least 2 weeks before your first dose of FABHALTA:

VACCINE	PURPOSE
Pneumococcal	Helps protect you from the risk of pneumonia caused by <i>Streptococcus pneumoniae</i> infection
Meningococcal	Helps protect you from the risk of meningitis caused by <i>Neisseria meningitidis</i> infection

If you have been vaccinated against these bacteria in the past, you might need additional vaccinations before starting FABHALTA. Your health care provider will decide if you need additional vaccinations.

Ask your doctor about any additional vaccines that may be helpful.

Vaccines do not prevent all infections caused by encapsulated bacteria.

Tell your health care provider or get emergency medical care right away if you get any of these signs and symptoms of a serious infection:

- Fever with or without shivers or chills
- Fever with high heart rate
- Fever and rash
- Headache with stiff neck or stiff back
- Fever with chest pain and cough
- Headache and fever
- Fever with breathlessness or fast breathing
- Body aches with flu-like symptoms
- Confusion
- Headache with nausea or vomiting
- Eyes sensitive to light
- Clammy skin


Please see Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

 **FABHALTA[®]**
(iptacopan) 200 mg capsules

PREPARING TO START FABHALTA: VACCINATIONS AND TIMING

Your health care provider will review your vaccination history and guide you through the dosing and scheduling options

This chart can help you understand what is needed to start FABHALTA:



While taking FABHALTA, you should be revaccinated according to current medical guidelines for encapsulated bacteria. Your health care provider or [Novartis Patient Support™](#) can help you locate vaccinations.

*Some vaccines may require more than 1 dose, so it's important to know how many doses you need for each.

Please see Important Safety Information throughout and on pages 12–13, and full [Prescribing Information](#), including Boxed WARNING and [Medication Guide](#).

 **FABHALTA[®]**
(iptacopan) 200 mg capsules

THE FABHALTA REMS PROGRAM

Because of the risk of serious infection that comes with taking FABHALTA, it is only available through a restricted program called a Risk Evaluation and Mitigation Strategy (REMS)



Before you can take FABHALTA, your health care provider must:

- Enroll in the FABHALTA REMS program
- Counsel you about the risk of serious infections caused by certain bacteria
- Give you written information about the symptoms of serious infections
- Make sure that you are vaccinated against serious infections caused by encapsulated bacteria
- Make sure that you receive antibiotics if you need to start FABHALTA right away and you are not up-to-date on your vaccinations
- Give you a **Patient Safety Card** about your risk of serious infections, as discussed below

The FABHALTA Patient Safety Card

Your health care provider will give you a Patient Safety Card about the risk of serious infections. Carry this card with you at all times during treatment and for 2 weeks after your last dose of FABHALTA. Your risk of serious infections may continue for a few weeks after your last dose of FABHALTA. It is important to show this card to any health care provider who treats you. This will help them diagnose and treat you quickly.

If you notice any signs or symptoms described on this card, contact your health care provider or get emergency medical assistance immediately.

To learn more about the FABHALTA REMS program, please call the REMS helpline at 1-866-201-3101 between 8:00 AM and 4:00 PM ET or visit [FABHALTA-REMS.com](https://www.fabhalta-rems.com).

Please see additional Important Safety Information throughout and on pages 12–13, and full [Prescribing Information](#), including [Boxed WARNING](#) and [Medication Guide](#).

 **FABHALTA[®]**
(iptacopan) 200 mg capsules

APPROVED USE AND IMPORTANT SAFETY INFORMATION FOR FABHALTA (iptacopan)

Approved Use

What is FABHALTA?

FABHALTA is a prescription medicine used to treat adults with a kidney disease called complement 3 glomerulopathy (C3G), to reduce protein in the urine (proteinuria). It is not known if FABHALTA is safe and effective in children with C3G.

Important Safety Information

What is the most important information I should know about FABHALTA?

FABHALTA is a medicine that affects part of your immune system and may lower your ability to fight infections.

- **FABHALTA increases your chance of getting serious infections caused by encapsulated bacteria**, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.
 - You must complete or update your vaccinations against *Streptococcus pneumoniae* and *Neisseria meningitidis* at least 2 weeks before your first dose of FABHALTA.
 - If you have not completed your vaccinations and FABHALTA must be started right away, you should receive the required vaccinations as soon as possible.
 - If you have not been vaccinated and FABHALTA must be started right away, you should also receive antibiotics to take for as long as your health care provider tells you.
 - If you have been vaccinated against these bacteria in the past, you might need additional vaccinations before starting FABHALTA. Your health care provider will decide if you need additional vaccinations.

- Vaccines do not prevent all infections caused by encapsulated bacteria. **Tell your health care provider or get emergency medical care right away if you get any of these signs and symptoms of a serious infection:**

- | | |
|---|---|
| ▪ Fever with or without shivers or chills | ▪ Fever and rash |
| ▪ Fever with chest pain and cough | ▪ Fever with breathlessness or fast breathing |
| ▪ Fever with high heart rate | ▪ Headache with nausea or vomiting |
| ▪ Headache and fever | ▪ Headache with stiff neck or stiff back |
| ▪ Confusion | ▪ Body aches with flu-like symptoms |
| ▪ Clammy skin | ▪ Eyes sensitive to light |

Your health care provider will give you a Patient Safety Card about the risk of serious infections. Carry it with you at all times during treatment and for 2 weeks after your last dose of FABHALTA. Your risk of serious infections may continue for a few weeks after your last dose of FABHALTA. It is important to show this card to any health care provider who treats you. This will help them diagnose and treat you quickly.

FABHALTA is only available through a program called the FABHALTA Risk Evaluation and Mitigation Strategy (REMS). Before you can take FABHALTA, your health care provider must:

- Enroll in the FABHALTA REMS program.
- Counsel you about the risk of serious infections caused by certain bacteria.
- Give you written information about the symptoms of serious infections.
- Make sure that you are vaccinated against serious infections caused by encapsulated bacteria.
- Make sure you receive antibiotics if you need to start FABHALTA right away and you are not up-to-date on your vaccinations.
- Give you a **Patient Safety Card** about your risk of serious infections.

Please see additional Important Safety Information throughout and on page 13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

 **FABHALTA**[®]
(iptacopan) 200 mg capsules

APPROVED USE AND IMPORTANT SAFETY INFORMATION FOR FABHALTA (iptacopan)

Important Safety Information (continued)

Who should NOT take FABHALTA?

Do not take FABHALTA if you:

- Are allergic to FABHALTA or any of the ingredients in FABHALTA.
- Have a serious infection caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, or *Haemophilus influenzae* type b, when you start FABHALTA.

Before you take FABHALTA, tell your health care provider about all your medical conditions, including if you:

- Have an infection or fever.
- Have liver problems.
- Are pregnant or plan to become pregnant. It is not known if FABHALTA will harm your unborn baby.
- Are breastfeeding or plan to breastfeed. It is not known if FABHALTA passes into your breast milk. You should not breastfeed during treatment and for 5 days after your final dose of FABHALTA.

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking FABHALTA with certain other medicines may affect the way FABHALTA works and may cause side effects.

Know the medicines you take and the vaccines you receive. Keep a list of them to show your health care provider and pharmacist when you get a new medicine.

What are the possible side effects of FABHALTA?

FABHALTA may cause serious side effects, including:

- See “What is the most important information I should know about FABHALTA?”
- **Increased cholesterol and triglyceride (lipid) levels in your blood.** Your health care provider will do blood tests to check your cholesterol and triglycerides during treatment with FABHALTA. Your health care provider may start you on a medicine to lower your cholesterol if needed.

The most common side effects of FABHALTA in adults include:

- | | |
|--|------------------------------------|
| • Headache | • Feeling dizzy |
| • Nasal congestion, runny nose, cough, sneezing, and sore throat (nasopharyngitis) | • Pain in the stomach (abdomen) |
| • Diarrhea | • Infections (bacterial and viral) |
| | • Nausea |
| | • Rash |

Tell your health care provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of FABHALTA.

Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout and on page 12, and full Prescribing Information, including Boxed WARNING and Medication Guide.

 **FABHALTA**[®]
(iptacopan) 200 mg capsules

FABHALTA CAN FIT INTO YOUR DAILY ROUTINE



1 capsule. Twice a day.

- Each capsule contains 200 mg
- Take 1 capsule twice a day with or without food
- Swallow the capsules whole
- **Do not** open, break, or chew capsules
- No refrigeration requirement*



What to do if you miss a dose or doses

If a dose or doses are missed, take 1 dose of FABHALTA as soon as you remember, even if it is almost time to take your next scheduled dose. Then take your next dose at your regularly scheduled time.

Take FABHALTA exactly as your doctor tells you. Do not change the dose or stop taking FABHALTA unless your doctor tells you.

*Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C and 30 °C (59 °F and 86 °F).

Important Safety Information (continued)

What are the possible side effects of FABHALTA?

FABHALTA may cause serious side effects, including:

- See “What is the most important information I should know about FABHALTA?”
- **Increased cholesterol and triglyceride (lipid) levels in your blood.** Your health care provider will do blood tests to check your cholesterol and triglycerides during treatment with FABHALTA. Your health care provider may start you on a medicine to lower your cholesterol if needed.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

Patient portrayal.



 **FABHALTA[®]**
(iptacopan) 200 mg capsules

ACCESS TO FABHALTA WITHIN REACH

FABHALTA access in 3 steps

	 1. Gain insurance approval	 2. Pay for FABHALTA	 3. Receive FABHALTA
What to expect	Your doctor's office will submit a prior authorization to your insurance company. Most are approved within a few weeks.	There are programs available to help you pay for FABHALTA.	A specialty pharmacy will reach out to coordinate shipment with you. - You will receive a 30-day supply - The specialty pharmacy should call you to reschedule your refill 5 to 10 days before you run out - If you are running low on your medication and haven't heard from your specialty pharmacy, call them ASAP
What you can do	Call your doctor's office if you don't hear anything after 2 weeks.	Ask your pharmacist about affordability programs you may qualify for.	You must answer the phone or return pharmacy phone calls to schedule your FABHALTA delivery. Specialty pharmacies that dispense FABHALTA: - Biologics by McKesson (800-850-4306) - CareMed[‡] (877-227-3405) Please make sure that the specialty pharmacy's phone number has not been blocked by your phone or carrier. Please make sure to check your voicemail and give them a call back. For patients in Puerto Rico, please contact Medplus Solutions (787-523-3888).
Available support	The FABHALTA Bridge Program offers up to 12 months of FABHALTA for free for privately insured eligible patients while insurance coverage is pursued. See terms and conditions on page 17.	You may be eligible for the \$0 Co-Pay Plus offer. See terms and conditions on page 17.	A dedicated Novartis Patient Support team will provide ongoing support throughout your FABHALTA treatment. Novartis does not recommend or require the use of any particular pharmacy. Data on file. FABHALTA Novartis Hub Patient Services and Specialty Pharmacy payer coverage outcome data. Novartis Pharmaceuticals Corp; 2026.
	90% of all prior authorizations are approved for FABHALTA C3G*	93% of C3G patients paid \$10 or less per month [†]	

*Between March 2024 and July 2026.

[†] Specialty pharmacy data from August 2025 to July 2026 for 1,396 prescriptions which represents approximately 99% of total prescriptions. For remaining people, the out-of-pocket cost for the product varies and may be as high as the total cost of the product.

[‡] CareMed is a subsidiary of Onco360.

The information provided is not a guarantee of coverage. Actual benefits are determined by each plan administrator in accordance with its policies and procedures. Because formularies change and many health plans offer more than one formulary, please check with the health plan to confirm coverage for individual patients.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

 **FABHALTA[®]**
(iptacopan) 200 mg capsules

YOUR CONDITION MAY BE RARE, BUT SUPPORT ISN'T

Novartis Patient Support can help you every step of the way

Now that you've been prescribed FABHALTA, you have support in your corner. Start, stay, and save on FABHALTA with the help of Novartis Patient Support.



Gain Insurance Support

Novartis Patient Support will work with your provider to help navigate insurance coverage for FABHALTA.



Financial Support

If you have private insurance, you may be eligible for the **\$0 Co-Pay Plus*** offer for FABHALTA. If you have private insurance and are eligible, the **Bridge Program[†]** offers up to 12 months of FABHALTA for free while insurance coverage is pursued.



Get FABHALTA

Your specialty pharmacy may help with medication education, insurance approval, affordability programs, and refill reminders.

- If you need help getting your vaccinations before starting FABHALTA, the Vaccination Support program provides in-home vaccinations or guided navigation to help find a vaccination location near you or provide guidance on accessing existing records.

Sign up for Novartis Patient Support

There are a few ways to start getting support:

- 1** Call 833-99FABHA (833-993-2242), Monday-Friday, 8:00 AM-8:00 PM ET, excluding holidays. Your dedicated Novartis Patient Support team can then help you sign up
- 2** Sign up online at support.FABHALTA.com
- 3** Ask your health care provider to help sign you up at your next appointment

*Please see [next page](#) for terms and conditions.

†Please see [next page](#) for terms and conditions.

The information provided is not a guarantee of coverage. Actual benefits are determined by each plan administrator in accordance with its policies and procedures. Because formularies change and many health plans offer more than one formulary, please check with the health plan to confirm coverage for individual patients.

Please see additional Important Safety Information throughout and on pages 12–13, and full [Prescribing Information](#), including Boxed WARNING and [Medication Guide](#).

 **FABHALTA[®]**
(iptacopan) 200 mg capsules

NEED FINANCIAL SUPPORT? WE'RE HERE TO HELP.

\$0 Co-Pay Plus* offer

If you have private insurance, you may be eligible for the \$0 Co-Pay Plus offer for FABHALTA through Novartis Patient Support. The information provided is not a guarantee of coverage. Actual benefits are determined by each plan administrator in accordance with its policies and procedures. Because formularies change and many health plans offer more than one formulary, please check with the health plan to confirm coverage for individual patients.

FABHALTA Bridge Program[†]

If you have private or commercial insurance, the FABHALTA Bridge Program offers up to 12 months of FABHALTA for free while we work with your health care provider and health insurance to help get your medication covered.

**To enroll in Novartis Patient Support, call
833-99FABHA (833-993-2242) or click here.**



***Co-Pay Plus:** Limitations apply. Patients with private insurance coverage for FABHALTA may receive up to \$20,000 in annual co-pay benefits for the cost of FABHALTA and up to \$1,000 for qualifying vaccination costs (excluding administrative fees). Patient is responsible for any costs once the limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this Program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Patient may not seek reimbursement for the value received from this Program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States, Puerto Rico, and select territories. Void where prohibited by law. Additional restrictions may apply. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend this Program and discontinue support at any time without notice.

†Bridge Program: The Bridge Program applies to FABHALTA only. Eligible patients must have private insurance and a valid prescription for FABHALTA, and a prior authorization or an initial denial of coverage. Program requires the submission of a prior authorization or an appeal of the coverage denial within the first 45 days of enrollment to remain eligible. Program provides FABHALTA for free to eligible patients for up to 12 months, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the Program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Additional limitations may apply. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

 **FABHALTA[®]**
(iptacopan) 200 mg capsules



Patient
portrayal.

***“I think not being
afraid to ask for help
would be the most
important part.
Give yourself grace
and breathe through
the changes.”***

— Real C3G patient

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

 **FABHALTA[®]**
(iptacopan) 200 mg capsules

18

Patient Support
& PCL

PATIENT & COMMUNITY LIAISONS ARE HERE TO SUPPORT YOU

You have a dedicated team in your corner

Living with a rare condition can feel isolating. Patient & Community Liaisons (PCLs) provide education, resources, and personalized support to help you understand and navigate your disease journey.



FABHALTA PCLs are here to:

- Engage with you and others like you affected by your condition. PCL engagement also extends to care partners and local community advocacy partners
- Educate the community and help affected people access helpful information
- Build relationships with local community and advocacy groups to help identify opportunities for support and connection within the community

PCLs do not provide medical advice.



Reach out to us at 877-FABPCLs (877-322-7257)

We look forward to connecting with you!

Grow your support system by connecting with a PCL today

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

 **FABHALTA[®]**
(iptacopan) 200 mg capsules

THE POWER OF SUPPORT & SELF-ADVOCACY

Make the most of tools and organizations that are here to help you

If you or a loved one has been diagnosed with C3G, it's reassuring to know that resources are available to support you before, during, and after any appointments. By taking advantage of these tools, you can better communicate with the care team so they can support you through your journey.

There's a wide range of tools to help you advocate for yourself. You could:

- [Talk to a PCL](#) to learn more about C3G and FABHALTA
- Use the [Doctor Discussion Guide](#) to help prepare for your doctor's visit
- Once prescribed FABHALTA, enroll in [Novartis Patient Support](#) for support every step of the way



Connecting with a community

When dealing with a rare disease, support from a community can make a difference. People who've been where you are now can help you. They can share personal experiences with others in the C3G community. What's more, there are groups to support you operating at national, local and social levels.



Help with vaccinations

If you need help getting your vaccinations before starting FABHALTA, the Vaccination Support program provides in-home vaccinations or guided navigation to help find a vaccination location near you or provide guidance on accessing existing records.

Click here to download helpful resources



Please see additional Important Safety Information throughout and on pages **12–13**, and full [Prescribing Information](#), including **Boxed WARNING** and [Medication Guide](#).

 **FABHALTA[®]**
(iptacopan) 200 mg capsules

20

TAKE THE NEXT STEP IN YOUR C3G JOURNEY



The first and only FDA-approved oral treatment for adults with C3G, to reduce proteinuria



Substantial proteinuria reduction at 6 months compared to placebo in adults with C3G who had never received a kidney transplant*:

-30% reduction with FABHALTA

+8% increase with placebo

The most common side effects of FABHALTA in adults include: headache; nasal congestion, runny nose, cough, sneezing, and sore throat (nasopharyngitis); diarrhea; feeling dizzy; pain in the stomach (abdomen); infections (bacterial and viral); nausea; rash.

There is a risk of serious infections while taking FABHALTA. Because of this risk, FABHALTA is only available through a REMS program that requires vaccinations. See page 9 for more information on vaccinations. See page 11 for more on the FABHALTA REMS program.

*In a clinical study of adult patients with biopsy-confirmed C3G who had never received a kidney transplant. Safety and effectiveness of FABHALTA in patients with recurrent C3G following kidney transplant have not been established. Efficacy results were analyzed at 6 months in 74 adults. 38 patients took 200 mg FABHALTA twice daily and 36 patients took placebo (sugar pill) twice daily. All patients were on a stable dose of maximally tolerated blood pressure medications (ACEi/ARB) with or without other background therapies 90 days prior to the study and throughout the study. See page 5 for full Study Design details.

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; REMS, Risk Evaluation and Mitigation Strategy.

Approved Use

What is FABHALTA?

FABHALTA is a prescription medicine used to treat adults with a kidney disease called complement 3 glomerulopathy (C3G), to reduce protein in the urine (proteinuria).

It is not known if FABHALTA is safe and effective in children with C3G.

Important Safety Information

What is the most important information I should know about FABHALTA?

FABHALTA is a medicine that affects part of your immune system and may lower your ability to fight infections.

- **FABHALTA increases your chance of getting serious infections caused by encapsulated bacteria**, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.

Please see additional Important Safety Information throughout and on pages 12-13, and full [Prescribing Information](#), including [Boxed WARNING](#) and [Medication Guide](#).



Patient portrayals.

Personalized education and support throughout your journey

- Learn more about C3G and FABHALTA. Call a Patient & Community Liaison at 877-322-7257.
- Help you start, stay, and save on FABHALTA. Call Novartis Patient Support at 833-993-2242.



FABHALTA[®]
(iptacopan) 200 mg capsules

 **NOVARTIS**

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080
© 2026 Novartis 8/26 FA-11753564